A synthetic peptide for use as a blocking control in assays to test for specificity of GCK antibody, Alternative Names: GCK control peptide, GCK antibody Blocking Peptide, Anti-GCK Blocking Peptide, glucokinase, hexokinase 4 Blocking Peptide, FGQTL3 Blocking Peptide, GK Blocking Peptide, GLK Blocking Peptide, HHF3 Blocking Peptide, HK4 Blocking Peptide, HKIV Blocking Peptide, HXKP Blocking Peptide, MODY2 Blocking Peptide
Optimal conditions should be determined by the investigator
Beschränkungen
Nur für Forschungszwecke einsetzbar
Format
Lyophilized
Rekonstitution
Add 100 µL of distilled water for a final peptide concentration is 1 mg/mL.
Buffer
PBS
Handhabung
Avoid repeated freeze/thaw cycles.
Lagerung
-20 °C
Informationen zur Lagerung
Store at -20 °C long term.
Target
GCK
(Glucokinase (Hexokinase 4) (GCK))
Hintergrund
Hexokinases phosphorylate glucose to produce glucose-6-phosphate, the first step in most glucose metabolism pathways. Alternative splicing of this gene results in three tissue-specific forms of glucokinase, one found in pancreatic islet beta cells and two found in liver. The protein localizes to the outer membrane of mitochondria. In contrast to other forms of hexokinase, this enzyme is not inhibited by its product glucose-6-phosphate but remains active while glucose is abundant. Mutations in this gene have been associated with non-insulin dependent diabetes mellitus (NIDDM), maturity onset diabetes of the young, type 2 (MODY2) and persistent hyperinsulinemic hypoglycemia of infancy (PHHI).